ABOUT REVCOVI (elapegademase-lvlr)
Revcovi is an enzyme replacement therapy (ERT) indicated for the treatment of adenosine deaminase severe combined immune deficiency (ADA-SCID) in pediatric and adult patients.1
Revcovi is the product of recombinant technology. It is a PEGylated recombinant adenosine deaminase (rADA) enzyme.1
Hear about Ashley's Revcovi treatment journey and her experience living with ADA-SCID
DOSING AND ADMINISTRATION
Dose titration along with careful lab monitoring helps customize Revcovi treatment to each patient’s individual needs.1
REVCOVI ORDERING & SUPPORT
Chiesi offers patient support services through Chiesi Total Care to aid patients, caregivers, and healthcare providers with coverage and reimbursement concerns.
REVCOVI HEALTHCARE PROFESSIONALS BROCHURE
Download a brochure about Revcovi, including efficacy and safety data, dosing and monitoring information, how to order, patient support programs, and information about diagnosing ADA-SCID.
ABOUT CHIESI GLOBAL RARE DISEASES
Chiesi Global Rare Diseases is committed to helping address mental wellness within the rare disease community.
We strive to revolutionize the lives of people living with rare diseases. We work in close partnership with caregivers, patient communities, healthcare professionals, government authorities, and other stakeholders to build a brighter future for all. We relentlessly pursue sustainable development goals with passion, courage, teamwork, and innovation. We believe, from timely and accurate diagnoses to receiving effective treatments and finding supportive communities, no one should feel left behind.
IMPORTANT SAFETY INFORMATION
WARNINGS AND PRECAUTIONS
- Injection site bleeding in patients with thrombocytopenia: Increased risk of local bleeding in patients with thrombocytopenia; should not be used if thrombocytopenia is severe.
- Delay in improvement of immune function: Protect immune deficient patients from infections until improvement in immune function.
ADVERSE REACTIONS
The most commonly reported adverse reactions were cough (50%) and vomiting (33%).
In addition, the following post-marketing reports for the same class of enzyme replacement therapy used in the treatment of ADA-SCID may also be seen with Revcovi treatment:
- Hematologic events: hemolytic anemia, autoimmune hemolytic anemia, thrombocythemia, thrombocytopenia and autoimmune thrombocytopenia
- Dermatological events: injection site erythema, urticaria
- Lymphomas
IMPORTANT MONITORING INFORMATION
Treatment with Revcovi should be monitored by measuring trough plasma ADA activity and trough dAXP levels for maintenance of therapeutic targets. If a persistent decline in plasma ADA activity occurs, immune function and clinical status should be monitored closely, and precautions should be taken to minimize the risk of infection.
INDICATION
Revcovi® (elapegademase-lvlr) is indicated for the treatment of adenosine deaminase severe combined immune deficiency (ADA-SCID) in pediatric and adult patients.
Please see the Full Prescribing Information.
IMPORTANT SAFETY INFORMATION
WARNINGS AND PRECAUTIONS
- Injection site bleeding in patients with thrombocytopenia: Increased risk of local bleeding in patients with thrombocytopenia; should not be used if thrombocytopenia is severe.
- Delay in improvement of immune function: Protect immune deficient patients from infections until improvement in immune function.
ADVERSE REACTIONS
The most commonly reported adverse reactions were cough (50%) and vomiting (33%).
In addition, the following post-marketing reports for the same class of enzyme replacement therapy used in the treatment of ADA-SCID may also be seen with Revcovi treatment:
- Hematologic events: hemolytic anemia, autoimmune hemolytic anemia, thrombocythemia, thrombocytopenia and autoimmune thrombocytopenia
- Dermatological events: injection site erythema, urticaria
- Lymphomas
IMPORTANT MONITORING INFORMATION
Treatment with Revcovi should be monitored by measuring trough plasma ADA activity and trough dAXP levels for maintenance of therapeutic targets. If a persistent decline in plasma ADA activity occurs, immune function and clinical status should be monitored closely, and precautions should be taken to minimize the risk of infection.
INDICATION
Revcovi® (elapegademase-lvlr) is indicated for the treatment of adenosine deaminase severe combined immune deficiency (ADA-SCID) in pediatric and adult patients.
Please see the Full Prescribing Information.
- Revcovi. Prescribing information. Chiesi USA, Inc.; 2021.